



STUDY	POPULATION	LOCATIONS	REGIMEN/RESULTS
<p>iPrEx</p> <p>Phase III trial that evaluated the safety and efficacy of once-daily oral Truvada to prevent HIV infection in gay men, other men who have sex with men (MSM) and transgender women.</p> <p>For more information: www.avac.org/trial/iprex</p>	<ul style="list-style-type: none"> • 2,499 gay men • other MSM • transgender women 	<ul style="list-style-type: none"> • Brazil • Ecuador • Peru • South Africa • Thailand • US 	<ul style="list-style-type: none"> • Daily oral Truvada showed 44% efficacy
<p>TDF2 Study</p> <p>Phase II/III trial that evaluated the safety of once-daily oral Truvada in heterosexual men and women.</p> <p>For more information: www.avac.org/trial/tdf2</p>	<ul style="list-style-type: none"> • 1,200 men and women 	<ul style="list-style-type: none"> • Botswana 	<ul style="list-style-type: none"> • Daily oral Truvada showed 62% efficacy
<p>Partners PrEP Study</p> <p>Phase III trial that evaluated the safety and efficacy of two different strategies to prevent HIV transmission in HIV-serodiscordant couples: once-daily oral tenofovir and once-daily oral Truvada.</p> <p>For more information: www.avac.org/trial/partners-prep</p>	<ul style="list-style-type: none"> • 4,758 serodiscordant heterosexual couples 	<ul style="list-style-type: none"> • Kenya • Uganda 	<ul style="list-style-type: none"> • Daily oral Truvada showed 75% efficacy • Daily oral tenofovir showed 67% efficacy
<p>Bangkok Tenofovir Study (CDC 4370)</p> <p>Phase II/III trial that evaluated the safety and efficacy of once-daily oral tenofovir to prevent HIV infection in people who inject drugs.</p> <p>For more information: www.avac.org/trial/cdc-4370-bangkok-tenofovir-study</p>	<ul style="list-style-type: none"> • 2,400 people who inject drugs 	<ul style="list-style-type: none"> • Thailand 	<ul style="list-style-type: none"> • Daily oral tenofovir showed 49% efficacy
<p>FEM-PrEP</p> <p>Phase III trial that evaluated the safety and effectiveness of once-daily oral Truvada for HIV prevention in women.</p> <p>For more information: www.avac.org/trial/fem-prep</p>	<ul style="list-style-type: none"> • 1,950 women 	<ul style="list-style-type: none"> • Kenya • South Africa • Tanzania 	<ul style="list-style-type: none"> • Daily oral Truvada showed no effect
<p>VOICE (MTN 003)</p> <p>Phase IIb trial that evaluated the safety and effectiveness of three different strategies to prevent HIV in women: once-daily oral tenofovir, oral Truvada, and vaginal tenofovir gel.</p> <p>For more information: www.avac.org/trial/mtn-003-voice</p>	<ul style="list-style-type: none"> • 5,029 women 	<ul style="list-style-type: none"> • South Africa • Uganda • Zimbabwe 	<ul style="list-style-type: none"> • Daily oral tenofovir showed no effect • Daily oral Truvada showed no effect • Daily vaginal tenofovir gel showed no effect



 efficacy related to regular dosing of PrEP

 overall efficacy, includes people who took PrEP as prescribed as well as those who didn't

* tenofovir only

** CDC reported data, not statistically significant

PrEP efficacy is **strongly associated** with adherence.